ClinicalTrials.gg
CompletedNCT03769090MANDALAUpdated Sep 28, 2022Results posted

A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma

A Phase 3 interventional study of Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg and Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg in Asthma, sponsored by Bond Avillion 2 Development LP. Completed at 345 sites in 11 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2022-09-28.

Sponsored by Bond Avillion 2 Development LP · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
3,132
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,695 studies in Asthma with a site in United States — 135 open to participants now, 188 under way, 19 of them phase 3. Asthma · United States.

Enrollment
17th of 1,353
3,132 · median 100
Started
2018
with 67 others
Phase 3
254 of 1,695
14 open now
Registered
1,280th of 1,695
by date

Among the 1,695 studies in Asthma with a site in United States, this one is the 17th largest by enrollment of the 1,353 interventional ones that give a count, is one of 68 that started in 2018, is one of 254 in phase 3, and was the 1,280th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

135 of the 1,695 studies in Asthma with a site in United States are open now. Recruiting first, the newest first:

130 more — sign in →

All 135 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,695 studies in Asthma with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, multicenter, parallel-group, variable-length study to compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma exacerbation in adult, adolescent, and pediatric subjects with moderate to severe asthma.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male aged ≥4 years at the time of
  2. Physician diagnosis of asthma documented for at least 1 year
  3. Receiving 1 of the following scheduled asthma maintenance therapies for 3 months with stable dosing for at least the last 4 weeks before Visit 1:

    • Medium-to-high-dose inhaled (ICS)
    • Medium-to-high-dose ICS and 1 additional maintenance therapy from the following: leukotriene receptor antagonists (LTRA), long-acting muscarinic antagonists (LAMA), or theophylline
    • Low-to-high-dose ICS in combination with long-acting β2-adrenoreceptor agonist (LABA) with or without one additional maintenance therapy from the following: LTRA, LAMA, or theophylline
  4. Prebronchodilator (FEV1) of ≥40 to \<90% predicted normal value for adults and adolescents, and ≥60 to \<100% predicted normal value for subjects aged 4 to 11 years after withholding specified medications including short/rapid-acting β2-adrenoreceptor agonist (SABA)
  5. Demonstrate reversibility at Visit 1, with an increase in FEV1 ≥12% (and ≥200 mL for subjects aged ≥18 years) relative to baseline after administration of sponsor provided Ventolin via central spirometry. One re-test for reversibility testing is allowed within the screening period in advance of Visit 2
  6. Demonstrate acceptable spirometry performance (i.e., meet American Thoracic Society/European Respiratory Society acceptability/repeatability criteria)
  7. A documented history of at least 1 severe asthma exacerbation within 12 months before Visit 1
  8. Able to perform acceptable and reproducible peak expiratory flow (PEF) measurements as assessed by the investigator

Exclusion criteria

Exclusion Criteria:

  1. or other significant lung disease (e.g., chronic bronchitis, emphysema, bronchiectasis with the need of treatment, cystic fibrosis, or bronchopulmonary dysplasia)
  2. Oral /SCS use (any dose and any indication) within 6 weeks before Visit 1
  3. Chronic use of oral corticosteroids (OCS, ≥3 weeks use in 3 months prior to Visit 1)
  4. Having received any marketed (e.g., omalizumab, mepolizumab, reslizumab, benralizumab) or biologic within 3 months or any other prohibited medication
  5. Current smokers, former smokers with >10 pack-years history, or former smokers who stopped smoking \<6 months before Visit 1 (including all forms of tobacco, e-cigarettes [vaping], and marijuana)
  6. Life-threatening asthma defined as any history of significant asthma episode(s) requiring intubation associated with hypercapnia, respiratory arrest, hypoxic seizures, or asthma related syncopal episode(s) within 5 years of Visit 1
  7. Historical or current evidence of a disease
  8. Cancer not in complete remission for at least 5 years
  9. Hospitalization for psychiatric disorder or attempted suicide within 1 year of Visit 1
  10. History of psychiatric disease, intellectual deficiency, poor motivation, or other conditions if their magnitude is limiting validity
  11. Significant abuse of alcohol or drugs
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
3,132 participants (actual)

Study arms

  • Experimental
    BDA MDI (PT027) 160/180 μg

    Budesonide/albuterol sulfate, BDA MDI, PT027 high dose

    Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg

  • Experimental
    BDA MDI (PT027) 80/180 μg

    Budesonide/albuterol sulfate, BDA MDI, PT027 low dose

    Combination Product: Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg

  • Active comparator
    AS MDI (PT007) 180 µg

    Albuterol sulfate MDI, PT007

    Drug: Albuterol sulfate metered-dose inhaler 180 μg

Interventions

  • Combination productBudesonide/albuterol sulfate metered-dose inhaler 160/180 μg

    Budesonide/albuterol sulfate combination inhalation aerosol

  • Combination productBudesonide/albuterol sulfate metered-dose inhaler 80/180 μg

    Budesonide/albuterol sulfate combination inhalation aerosol

  • DrugAlbuterol sulfate metered-dose inhaler 180 μg

    Albuterol sulfate inhalation aerosol

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Severe Asthma Exacerbation Event

    Time to first severe asthma exacerbation will be calculated as the time from randomization until the start date of the first severe asthma exacerbation. An asthma exacerbation will be considered severe if it results in at least one of the following: a temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening (a single depo-injectable dose of corticosteroids will be considered equivalent), an emergency room or urgent care visit (\<24 hours in the facility for evaluation and treatment) due to asthma that required systemic corticosteroids, or an in-patient hospitalization (admission to an in-patient facility and/or ≥ 24 hours in a healthcare facility) due to asthma. The descriptive summary shows the number of participants with a severe exacerbation event, occurring between the date of randomization up to the date of randomized treatment discontinuation or a change in maintenance therapy.

    Time frame: From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.

Secondary outcomes

  1. Annualized Severe Exacerbation Rate

    The annualized severe exacerbation rate (severe exacerbations per year) is estimated from a negative binomial model with treatment, age group, region, and number of severe exacerbations in the last 12 months prior to randomization as categorical covariates. The logarithm of the time at risk is included as an offset variable.

    Time frame: From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.

  2. Total Annualized Dose of Systemic Corticosteroid (SCS)

    This endpoint includes all systemic corticosteroids (SCS) taken in response to a severe exacerbation event from randomization up to randomized treatment discontinuation or a change in maintenance therapy. All SCS are standardized to equipotent doses of prednisone before deriving the total dose. The total annualized dose is calculated as the total dose of SCS divided by the duration of the randomized treatment period.

    Time frame: From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.

  3. Asthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24

    The ACQ-5 consists of 5 questions on symptom control, with each scored on a 7-point scale (0 = excellent asthma control; 6 = extremely poor control). The overall score (0 = excellent asthma control; 6 = extremely poor control, so a lower score is the better outcome) is the mean of the 5 symptom items. A responder is defined as a participant with a decrease from baseline to Week 24 overall ACQ-5 score of 0.5 or more. ACQ-5 is not validated for children less than 6 years old, data for participants who were 4 or 5 years old was excluded from the analysis of ACQ-5.

    Time frame: From baseline to Week 24

  4. Asthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24

    The AQLQ+12 consists of 32 questions in 4 domains and is assessed on separate 7-point Likert scales from 1 to 7, with higher values indicating better health-related quality of life. The overall score is the mean of all responses. A responder is defined as a participant with an increase from baseline to week 24 AQLQ-12 score of at least 0.5.

    Time frame: From baseline to 24 weeks

07

Results

Posted Sep 28, 2022

Participant flow

The first subject enrolled on 13 December 2018 and the last subject completed the study on 07 February 2022. Subjects were enrolled at 347 study centers worldwide (Argentina, Canada, Czechia, Germany, Serbia, Slovakia, South Africa, Spain, Ukraine, United Kingdom and the United States).

Participant flow — Overall Study
MilestoneBDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µg
Started101610571059
Completed915933916
Not completed101124143
Withdrew: Randomized and did not receive randomized study treatment122
Withdrew: Withdrawal by subject526274
Withdrew: Death422
Withdrew: Adverse event778
Withdrew: A single severe exacerbation event lasting >20 days012
Withdrew: >= 3 severe exacerbation events within a 3 month period144
Withdrew: >= 5 total severe exacerbation events011
Withdrew: Protocol violation568
Withdrew: Pregnancy103
Withdrew: Lost to follow-up192521
Withdrew: Condition under investigation worsened201
Withdrew: Lack of efficacy122
Withdrew: Other reasons81215

Outcome measures

PrimaryNumber of Participants With a Severe Asthma Exacerbation Event

Time to first severe asthma exacerbation will be calculated as the time from randomization until the start date of the first severe asthma exacerbation. An asthma exacerbation will be considered severe if it results in at least one of the following: a temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening (a single depo-injectable dose of corticosteroids will be considered equivalent), an emergency room or urgent care visit (\<24 hours in the facility for evaluation and treatment) due to asthma that required systemic corticosteroids, or an in-patient hospitalization (admission to an in-patient facility and/or ≥ 24 hours in a healthcare facility) due to asthma. The descriptive summary shows the number of participants with a severe exacerbation event, occurring between the date of randomization up to the date of randomized treatment discontinuation or a change in maintenance therapy.

Time frame:
From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.
Reported as:
Count of participants · Participants
Number of Participants With a Severe Asthma Exacerbation Event
ParticipantsBDA MDI 160/180 μg (Full Analysis Set; >=12 Years)AS MDI 180 μg (Full Analysis Set; >=12 Years)BDA MDI 80/180 μg (Full Analysis Set)AS MDI 180 μg (Full Analysis Set)
Number of Participants With a Severe Asthma Exacerbation Event207266241276
Statistical analysis
  • BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) vs AS MDI 180 μg (Full Analysis Set; >=12 Years) · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.733 · 95% CI 0.611 to 0.879
  • BDA MDI 80/180 μg (Full Analysis Set) vs AS MDI 180 μg (Full Analysis Set) · Regression, Cox · p = 0.041 · Hazard ratio (hr): 0.835 · 95% CI 0.702 to 0.992
SecondaryAnnualized Severe Exacerbation Rate

The annualized severe exacerbation rate (severe exacerbations per year) is estimated from a negative binomial model with treatment, age group, region, and number of severe exacerbations in the last 12 months prior to randomization as categorical covariates. The logarithm of the time at risk is included as an offset variable.

Time frame:
From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.
Reported as:
Least squares mean · Severe exacerbations per year
Annualized Severe Exacerbation Rate
Severe exacerbations per yearBDA MDI 160/180 μg (Full Analysis Set; >=12 Years)AS MDI 180 μg (Full Analysis Set; >=12 Years)BDA MDI 80/180 μg (Full Analysis Set)AS MDI 180 μg (Full Analysis Set)
Annualized Severe Exacerbation Rate0.45 (0.34 to 0.60)0.59 (0.44 to 0.78)0.49 (0.37 to 0.64)0.61 (0.46 to 0.80)
Statistical analysis
  • BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) vs AS MDI 180 μg (Full Analysis Set; >=12 Years) · Negative binomial model · p = 0.008 · Rate ratio: 0.76 · 95% CI 0.62 to 0.93
  • BDA MDI 80/180 μg (Full Analysis Set) vs AS MDI 180 μg (Full Analysis Set) · Negative binomial model · p = 0.028 · Rate ratio: 0.8 · 95% CI 0.66 to 0.98
SecondaryTotal Annualized Dose of Systemic Corticosteroid (SCS)

This endpoint includes all systemic corticosteroids (SCS) taken in response to a severe exacerbation event from randomization up to randomized treatment discontinuation or a change in maintenance therapy. All SCS are standardized to equipotent doses of prednisone before deriving the total dose. The total annualized dose is calculated as the total dose of SCS divided by the duration of the randomized treatment period.

Time frame:
From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.
Reported as:
Mean · Milligram(s)
Total Annualized Dose of Systemic Corticosteroid (SCS)
Milligram(s)BDA MDI 160/180 μg (Full Analysis Set; >=12 Years)AS MDI 180 μg (Full Analysis Set; >=12 Years)BDA MDI 80/180 μg (Full Analysis Set)AS MDI 180 μg (Full Analysis Set)
Total Annualized Dose of Systemic Corticosteroid (SCS)86.2 (0 to 3678)129.3 (0 to 18941)95.5 (0 to 4974)127.1 (0 to 18941)
Statistical analysis
  • BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) vs AS MDI 180 μg (Full Analysis Set; >=12 Years) · Wilcoxon rank sum · p = 0.002
  • BDA MDI 80/180 μg (Full Analysis Set) vs AS MDI 180 μg (Full Analysis Set) · Wilcoxon rank sum · p = 0.06
SecondaryAsthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24

The ACQ-5 consists of 5 questions on symptom control, with each scored on a 7-point scale (0 = excellent asthma control; 6 = extremely poor control). The overall score (0 = excellent asthma control; 6 = extremely poor control, so a lower score is the better outcome) is the mean of the 5 symptom items. A responder is defined as a participant with a decrease from baseline to Week 24 overall ACQ-5 score of 0.5 or more. ACQ-5 is not validated for children less than 6 years old, data for participants who were 4 or 5 years old was excluded from the analysis of ACQ-5.

Time frame:
From baseline to Week 24
Reported as:
Count of participants · Participants
Asthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24
ParticipantsBDA MDI 160/180 μg (Full Analysis Set; >=12 Years)AS MDI 180 μg (Full Analysis Set; >=12 Years)BDA MDI 80/180 μg (Full Analysis Set)AS MDI 180 μg (Full Analysis Set)
Asthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24677630681650
Statistical analysis
  • BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) vs AS MDI 180 μg (Full Analysis Set; >=12 Years) · Regression, Logistic · p = 0.033 · Odds ratio (or): 1.221 · 95% CI 1.016 to 1.467
  • BDA MDI 80/180 μg (Full Analysis Set) vs AS MDI 180 μg (Full Analysis Set) · Regression, Logistic · p = 0.175 · Odds ratio (or): 1.132 · 95% CI 0.946 to 1.353
SecondaryAsthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24

The AQLQ+12 consists of 32 questions in 4 domains and is assessed on separate 7-point Likert scales from 1 to 7, with higher values indicating better health-related quality of life. The overall score is the mean of all responses. A responder is defined as a participant with an increase from baseline to week 24 AQLQ-12 score of at least 0.5.

Time frame:
From baseline to 24 weeks
Reported as:
Count of participants · Participants
Asthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24
ParticipantsBDA MDI 160/180 μg (Full Analysis Set; >=12 Years)BDA MDI 80/180 μg (Full Analysis Set; >=12 Years)AS MDI 180 μg (Full Analysis Set; >=12 Years)
Asthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24508489461
Statistical analysis
  • BDA MDI 160/180 μg (Full Analysis Set; >=12 Years) vs AS MDI 180 μg (Full Analysis Set; >=12 Years) · Regression, Logistic · p = 0.028 · Odds ratio (or): 1.228 · 95% CI 1.022 to 1.475
  • BDA MDI 80/180 μg (Full Analysis Set; >=12 Years) vs AS MDI 180 μg (Full Analysis Set; >=12 Years) · Regression, Logistic · p = 0.26 · Odds ratio (or): 1.111 · 95% CI 0.925 to 1.335

Adverse events

Collected over Adverse events (AEs) were collected from the time of signed informed consent/assent and up to the safety follow up period. Reported AEs are those that occurred from the date of first dose of randomized treatment up to the date of treatment discontinuation, which per protocol, was expected to be at least 24 weeks. The mean and median duration of exposure to randomized treatment for the reporting period for all participants was 44 and 48 weeks, respectively.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
BDA MDI (PT027) 160/180 μg4/1,015 (0.4%)53/1,015 (5.2%)244/1,015 (24%)
BDA MDI (PT027) 80/180 μg2/1,055 (0.2%)40/1,055 (3.8%)253/1,055 (24%)
AS MDI (PT007) 180 µg2/1,057 (0.2%)48/1,057 (4.5%)243/1,057 (23%)
Most frequent serious events
Showing 10 of 93
Most frequent serious events
EventBDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µg
AsthmaRespiratory, thoracic and mediastinal disorders7/10158/105520/1057
COVID-19Infections and infestations11/10155/10558/1057
PneumoniaInfections and infestations5/10154/10552/1057
COVID-19 pneumoniaInfections and infestations3/10154/10555/1057
Cholecystitis acuteHepatobiliary disorders3/10150/10550/1057
InfluenzaInfections and infestations0/10153/10550/1057
Urinary tract infectionInfections and infestations0/10150/10553/1057
Atrial fibrillationCardiac disorders0/10152/10550/1057
Accelerated hypertensionVascular disorders1/10150/10550/1057
Deep vein thrombosisVascular disorders1/10150/10550/1057
Most frequent other events
Most frequent other events
EventBDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µg
NasopharyngitisInfections and infestations76/101561/105554/1057
HeadacheNervous system disorders44/101550/105549/1057
COVID-19Infections and infestations33/101547/105538/1057
Upper respiratory tract infectionInfections and infestations26/101531/105526/1057
Back painMusculoskeletal and connective tissue disorders27/101523/105520/1057
BronchitisInfections and infestations25/101527/105528/1057
HypertensionVascular disorders22/101527/105526/1057
SinusitisInfections and infestations15/101517/105525/1057
InfluenzaInfections and infestations21/101520/105514/1057

Baseline characteristics

Of the 3,132 participants randomized, the full analysis set across all ages comprises 3,127 participants as one participant was randomized and did not receive randomized study treatment, and four participants were randomized in error and did not receive randomized study treatment. These five participants have therefore been excluded from the summaries of baseline characteristics, efficacy and safety.

Age, Continuous
Age, Continuous(years)BDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µgTotal
Mean50.6 ± 15.0548.5 ± 16.7149.1 ± 17.2249.4 ± 16.39
Age, Customized
Age, Customized(Participants)BDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µgTotal
Children (>=4 to <12 years)0414283
Adolescents (>=12 to <18 years)343234100
Adults (>=18 to <65 years)7898057842378
Elderly (>=65 years)192177197566
Sex: Female, Male
Sex: Female, Male(Participants)BDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µgTotal
Female6476866952028
Male3683693621099
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)BDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µgTotal
Hispanic or Latino235261316812
Not Hispanic or Latino7807947412315
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)BDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µgTotal
American Indian or Alaska Native1102
Asian29332385
Native Hawaiian or Other Pacific Islander0000
Black or African American139141137417
White8208488692537
More than one race18202462
Unknown or Not Reported812424
Region of Enrollment
Region of Enrollment(Participants)BDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µgTotal
Canada19111242
Argentina157200207564
United States274275290839
Czechia746473211
Ukraine156150128434
South Africa106120115341
United Kingdom9151034
Slovakia25302883
Serbia655457176
Germany109108112329
Spain21282574
Height
Height(Centimeters)BDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µgTotal
Mean166.8 ± 9.92165.1 ± 11.45164.4 ± 11.67165.4 ± 11.10
Weight
Weight(Kilograms)BDA MDI (PT027) 160/180 μgBDA MDI (PT027) 80/180 μgAS MDI (PT007) 180 µgTotal
Mean80.5 ± 16.8878.2 ± 18.9378.8 ± 18.4779.2 ± 18.15

1 further baseline measures are reported on the registry.

08

Study locations

345 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Huntsville, Alabama 35801, United States
  • Research Site
    Mobile, Alabama 36608, United States
  • Research Site
    Montgomery, Alabama 36106, United States
  • Research Site
    Scottsboro, Alabama 35768, United States
  • Research Site
    Sheffield, Alabama 35660, United States
  • Research Site
    Tuscumbia, Alabama 35674, United States
  • Research Site
    Glendale, Arizona 85306, United States
  • Research Site
    Peoria, Arizona 85381, United States
  • Research Site
    Scottsdale, Arizona 85251, United States
  • Research Site
    Little Rock, Arkansas 72209, United States
  • Research Site
    Bakersfield, California 93301, United States
  • Research Site
    Bellflower, California 90706, United States
  • Research Site
    Canoga Park, California 91304, United States
  • Research Site
    Encinitas, California 92024, United States
  • Research Site
    Hawthorne, California 90250, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Los Angeles, California 90017, United States
  • Research Site
    Los Angeles, California 90025, United States
  • Research Site
    Los Angeles, California 90048, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Rancho Cucamonga, California 91730, United States
  • Research Site
    Redwood City, California 94063, United States
  • Research Site
    Sacramento, California 95823, United States
  • Research Site
    San Diego, California 92120, United States
  • Research Site
    San Francisco, California 94102, United States
  • Research Site
    San Jose, California 95117, United States
  • Research Site
    Westminster, California 92683, United States
  • Research Site
    Aurora, Colorado 80045, United States
  • Research Site
    Colorado Springs, Colorado 80907, United States
  • Research Site
    Colorado Springs, Colorado 80909, United States
  • Research Site
    Denver, Colorado 80206, United States
  • Research Site
    Denver, Colorado 80230, United States
  • Research Site
    Denver, Colorado 80246, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Boynton Beach, Florida 33436, United States
  • Research Site
    Cape Coral, Florida 33991, United States
  • Research Site
    Clearwater, Florida 33756, United States
  • Research Site
    Clearwater, Florida 33765, United States
  • Research Site
    DeLand, Florida 32720, United States
  • Research Site
    Gainesville, Florida 32653, United States
  • Research Site
    Greenacres City, Florida 33467, United States
  • Research Site
    Hialeah, Florida 33012, United States
  • Research Site
    Kissimmee, Florida 34741, United States
  • Research Site
    Miami, Florida 33125, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33135, United States
  • Research Site
    Miami, Florida 33144, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Miami, Florida 33174, United States
  • Research Site
    Miami, Florida 33175, United States
  • Research Site
    Miami, Florida 33186, United States
  • Research Site
    Orlando, Florida 32806, United States
  • Research Site
    Orlando, Florida 32819, United States
  • Research Site
    Oviedo, Florida 32765, United States
  • Research Site
    Palmetto Bay, Florida 33157, United States
  • Research Site
    Panama City, Florida 32405, United States
  • Research Site
    Pembroke Pines, Florida 33024, United States
  • Research Site
    Pembroke Pines, Florida 33026, United States
  • Research Site
    Saint Petersburg, Florida 33707, United States
  • Research Site
    Saint Petersburg, Florida 33710, United States
  • Research Site
    Albany, Georgia 31707, United States
  • Research Site
    Winder, Georgia 30680, United States
  • Research Site
    Meridian, Idaho 83646, United States
  • Research Site
    Chicago, Illinois 60644, United States
  • Research Site
    Normal, Illinois 61761, United States
  • Research Site
    Iowa City, Iowa 52242, United States
  • Research Site
    Overland Park, Kansas 66210, United States
  • Research Site
    Topeka, Kansas 66606, United States
  • Research Site
    Owensboro, Kentucky 42301, United States
  • Research Site
    Bangor, Maine 04401, United States
  • Research Site
    Baltimore, Maryland 21209, United States
  • Research Site
    Chevy Chase, Maryland 20815, United States
  • Research Site
    White Marsh, Maryland 21162, United States
  • Research Site
    Boston, Massachusetts 02115, United States
  • Research Site
    Fall River, Massachusetts 02723, United States
  • Research Site
    North Dartmouth, Massachusetts 02747, United States
  • Research Site
    Ann Arbor, Michigan 48106, United States
  • Research Site
    Ann Arbor, Michigan 48109, United States
  • Research Site
    Farmington Hills, Michigan 48336, United States
  • Research Site
    Flint, Michigan 48504, United States
  • Research Site
    Flint, Michigan 48507, United States
  • Research Site
    Hamtramck, Michigan 48212, United States
  • Research Site
    Rochester Hills, Michigan 48307, United States
  • Research Site
    Rochester, Michigan 48307, United States
  • Research Site
    Ypsilanti, Michigan 48197, United States
  • Research Site
    Hazelwood, Missouri 63042, United States
  • Research Site
    Saint Louis, Missouri 63110, United States
  • Research Site
    Saint Louis, Missouri 63141, United States
  • Research Site
    Bellevue, Nebraska 68005, United States
  • Research Site
    Bellevue, Nebraska 68123, United States
  • Research Site
    Lincoln, Nebraska 68505, United States
  • Research Site
    Las Vegas, Nevada 89106, United States
  • Research Site
    Brick, New Jersey 08724, United States
  • Research Site
    Marlton, New Jersey 08053, United States
  • Research Site
    New Brunswick, New Jersey 08901, United States
  • Research Site
    Toms River, New Jersey 08755, United States
  • Research Site
    Albuquerque, New Mexico 87131, United States
  • Research Site
    Bronx, New York 10461, United States

Showing the first 100 of 345 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Chipps BE, Albers FC, Reilly L, Johnsson E, Cappelletti C, Papi A. Efficacy and safety of as-needed albuterol/budesonide versus albuterol in adults and children aged >/=4 years with moderate-to-severe asthma: rationale and design of the randomised, double-blind, active-controlled MANDALA study. BMJ Open Respir Res. 2021 Dec;8(1):e001077. doi: 10.1136/bmjresp-2021-001077. PubMed 34887317 ↗
  • Papi A, Chipps BE, Beasley R, Panettieri RA Jr, Israel E, Cooper M, Dunsire L, Jeynes-Ellis A, Johnsson E, Rees R, Cappelletti C, Albers FC. Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. N Engl J Med. 2022 Jun 2;386(22):2071-2083. doi: 10.1056/NEJMoa2203163. Epub 2022 May 15. PubMed 35569035 ↗
  • Kew KM, Flemyng E, Quon BS, Leung C. Increased versus stable doses of inhaled corticosteroids for exacerbations of chronic asthma in adults and children. Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD007524. doi: 10.1002/14651858.CD007524.pub5. PubMed 36161875 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in Aug 2021, 32 months.

Results were first posted in Sep 2022, 1 year 1 month after primary completion.

Of 173 industry-sponsored phase 3 interventional studies under Asthma, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 32 months is above that.

Counting every sponsor, half of 205 studies reached it within 27 months; a quarter within 14 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2018
First posted
Dec 7, 2018
StartActual
Dec 13, 2018
Primary completionActual
Aug 19, 2021
CompletionActual
Feb 7, 2022
Results first posted
Sep 28, 2022
Last update
Sep 28, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03769090
Lead sponsor
Bond Avillion 2 Development LP
Responsible party
Sponsor
First posted
Dec 7, 2018
Start date
Dec 13, 2018
Primary completion
Aug 19, 2021
Completion
Feb 7, 2022
Results posted
Sep 28, 2022
Last update
Sep 28, 2022

Study contacts

Frank Albers, MD, PhD
study director · Avillion LLP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion